eligibility_summary
Adults 18–75 with advanced solid tumors after standard therapy (escalation: any, expansion: HCC, TNBC, others), RECIST lesion, ECOG 0–1, life >3 mo, adequate organ function (HCC Child‑Pugh ≤7), contraception. Exclude recent anti‑cancer therapy/trials, prior IMM2510/IMM27M or severe irAEs/allergy or anti‑CTLA‑4/PD‑1/L1 intolerance, active/untreated CNS mets, major CV/TE/resp/GI bleeding risk, active HBV/HCV/TB/HIV, autoimmune disease, immunosuppression, recent surgery, live vaccines, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, single-arm trial testing two immune-oncology antibodies in combination: IMM2510 and IMM27M. IMM2510 is an anti–PD-L1/VEGF bispecific antibody fusion protein (biologic) that simultaneously blocks the PD-1/PD-L1 checkpoint to restore T‑cell activity and neutralizes VEGF to inhibit tumor angiogenesis and VEGF-driven immunosuppression. IMM27M is a humanized, Fc‑engineered anti‑CTLA‑4 monoclonal antibody (checkpoint inhibitor) that enhances T‑cell priming by blocking CTLA‑4 and may deplete CTLA‑4high regulatory T cells via Fc-mediated effector functions. Targeted cells/pathways: PD-L1 on tumor and myeloid cells, CTLA‑4 on activated T cells/Tregs, VEGF–VEGFR signaling in tumor endothelium/stroma. Net intent: boost effector T‑cell responses, reduce Treg-mediated suppression, and normalize tumor vasculature in advanced solid tumors (expansion in TNBC and HCC).